When was AMILI founded?

AMILI was founded in 2019 and raised its 1st funding round 3 years after it was founded.

Where is AMILI located?

AMILI is headquartered in Singapore, Singapore. It is registered at Rīga, Mirdzas Ķempes iela 7 - 40.

Which legal entities is AMILI associated with?

AMILI is associated with AMILI PTE. LTD. and 1 other.

How many employees does AMILI have?

As of May 31, 2026, the latest employee count at AMILI is 57.

Is AMILI a funded company?

AMILI is a funded company, having raised a total of $10.5M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jun 15, 2022.

When was the latest funding round of AMILI?

AMILI's latest funding was a $***** Series A round on May 29, 2023, with participation from 1 investor.

What is the annual revenue of AMILI?

Annual revenue of AMILI is 1.85M SGD as on Apr 30, 2024.

Where does AMILI rank among its competitors?

AMILI ranks 3rd amongst 174 active competitors, of which 35 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Nextbiotix, which secured $3.32M in Oct, 2025.

Who are the top competitors of AMILI?

AMILI's top competitors include Novozymes, MaaT Pharma and Seed. Among them, Nextbiotix secured the most recent funding round in October, 2025.

AMILI - 2026 Company Profile, Team, Funding, Competitors & Financials

AMILI is a series A company based in Singapore (Singapore), founded in 2019 by Jeremy Lim, Christopher Ting, Jonathan Lee, Dennis Von Berlepsch and David Ong. It operates as a Provider of gut microbiome data insights, analytics, tests, and therapeutics. AMILI has raised $10.5M in funding from East Ventures and Vulcan Capital. The company has 174 active competitors, including 35 funded and 14 that have exited. Its top competitors include companies like Novozymes, MaaT Pharma and Seed.

Company Details

Provider of gut microbiome data insights, analytics, tests, and therapeutics. It offers a platform for understanding gut microbiome abundance, functionality, and health impact. It formulates microbiome-enabled products and services for industry partners. It offers proprietary gut health test kits and probiotics are available. t also develops therapeutics and diagnostics related to gut health.

Website: amili.asia
Phone Number: +65 **********
Registered Address: Rīga, Mirdzas Ķempes iela 7 - 40

Key Metrics

Founded Year

2019

Location

Singapore, Singapore

Stage

Series A

Total Funding

$10.5M in 2 rounds

Latest Funding Round

Series A, May 29, 2023, $*****

Investors

East Ventures & 9 more

Ranked

3^rd among 174 active competitors

Annual Revenue

1.85M SGD as on Apr 30, 2024

Employee Count

57 as on May 31, 2026

Similar Companies

Novozymes & 217 more

View AMILI's full profile

AMILI is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
AMILI PTE. LTD. CIN: 201922200N , Singapore, Active		$1.37M (As on Apr 30, 2024)	-
Amili CIN: 40103691450 , Latvia, Active	Jul 17, 2013	$250K (As on Dec 31, 2024)	2 (As on Dec 31, 2022)	-

AMILI has raised a total funding of $10.5M over 2 rounds. Its first funding round was on Jun 15, 2022. Its latest funding round was a Series A round on May 29, 2023 for $*****. 1 investor participated in its latest round. AMILI has 10 institutional investors.

Here is the list of recent funding rounds of AMILI:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 29, 2023	4679820	Series A	4422176	6428117	6386825	9794236
Jun 15, 2022	8317543	Series A	5007219	9277729	Vulcan Capital	Pruksa & 7 more

Access funding benchmarks and valuations. Sign up today!

View details of AMILI's funding rounds and investors

The founders of AMILI are Jeremy Lim, Christopher Ting, Jonathan Lee, Dennis Von Berlepsch and David Ong.

Here are the details of AMILI's key team members:

Jeremy Lim: Co-Founder of AMILI. They are also an angel investor in 1 startup and serve on the board of 1 company.
Christopher Ting: Co-Founder of AMILI.
Jonathan Lee: Co-Founder of AMILI.
Dennis Von Berlepsch: Co-Founder of AMILI.
David Ong: Co-Founder of AMILI.

AMILI's Board of Directors

AMILI's board has 2 active members. Jeremy Lim is part of team and Tommy Teo is independent board member.

Here is the list of AMILI's board of directors:

Name	Type	Representing	Status	Duration
Jeremy Lim	Team	-	Current	6y 8m
Ong Eng Hui David	Team	-	Current	6y 8m
Tommy Teo	Independent board member	-	Current	3y 9m
cwqubxj	Independent board member	-	Past	7y 9m

View details of AMILI's Founder profiles and Board Members

AMILI's employee count trend

AMILI has 57 employees as of May 26. Here is AMILI's employee count trend over the years:

Uncover AMILI's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of AMILI include Novozymes, MaaT Pharma and Seed. Here is the list of Top 10 competitors of AMILI, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Novozymes 2000, Bagsvaerd (Denmark), Acquired	Developer of biosolutions and enzymes for multiple industries and applications of biotechnology	$9.75M	DOE, CHV & 3 others	74/100
2nd	MaaT Pharma 2014, Lyon (France), Public	Developer of microbiome therapy for the treatment of intestinal dysbiosis diseases	$42.3M	Symbiosis, Credit Mutuel Equity & 11 others	65/100
3rd	AMILI 2019, Singapore (Singapore), Series A	Provider of gut microbiome data insights, analytics, tests, and therapeutics	$10.5M	Emtek, Vulcan Capital & 8 others	53/100
4th	Seed 2016, Los Angeles (United States), Series A	Developer of synbiotics for simulating gut microbiome	$40.6M	Greycroft, BoxGroup & 26 others	57/100
5th	Seres Therapeutics 2010, Cambridge (United States), Public	Developer of microbiome therapeutics to treat a wide range of diseases	$134M	Flagship Pioneering, Alexandria & 8 others	55/100
6th	Genome & Company 2015, Seongnam-si (South Korea), Public	Developer of microbiome-based immuno-oncology drugs	-	IMM Investment, Timefolio Capital & 8 others	55/100
7th	Resbiotic 2021, Birmingham (United States), Series A	Provider of probiotic supplements to improve health	$20.6M	Timberline, BioStack Ventures & 3 others	54/100
8th	Nextbiotix 2016, Dijon (France), Series A	Developer of probiotic for the treatment of inflammatory bowel diseases	$30.4M	Auriga Partners, UI Investissement & 10 others	54/100
9th	Sova Health 2019, Gurugram (India), Seed	Provider of a gut-health and personalised wellness supplements	$1.35M	Antler, LetsVenture & 12 others	53/100
10th	Rebiotix 2011, Roseville (United States), Acquired	Developing microbiota restoration therapy for the treatment of infectious diseases.	$29.3M	Sofia Fund, Lateral Capital & 5 others	52/100